At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 40 enrolled
Drug / intervention
0.5 mg ranibizumab +1 moredrug
Likely dose
0.5 mg ranibizumabfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Active-Controlled, Phase II Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation in Subjects With Radiation Retinopathy (RRR Study).
In Brief
A Phase 2 clinical trial evaluating 0.5 mg ranibizumab and Targeted Retinal Photocoagulation (TRP) for Radiation Retinopathy. Completed, enrolled 40 participants across 4 sites.
Detailed Summary
The purpose of this study is to assess the tolerability and efficacy of ranibizumab treatment administered in subjects with radiation retinopathy
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRadiation Retinopathy
CountriesUnited States
CollaboratorsGenentech, Inc.
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedAug 2014
Enrollment StartSep 2014
Primary CompletionMar 2019
TodayJul 2026
First PostedAug 21, 2014
Enrollment StartSep 23, 2014
Primary CompletionMar 1, 2019
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 11.9 years ago
Interventions
0.5 mg ranibizumabdrug
Targeted Retinal Photocoagulation (TRP)procedure
TRP to areas of retinal ischemia